| Literature DB >> 33291041 |
Arjun K Reddy1, Kaley Lulkovich2, Ryan Ottwell2, Wade Arthur2, Aaron Bowers2, Shafiq Al-Rifai3, Katherine Cook3, Drew N Wright4, Micah Hartwell5, Matt Vassar5.
Abstract
INTRODUCTION: It is predicted that erectile dysfunction will affect around 322 million men worldwide by 2025. Because of the large volume of literature on the topic, physicians often turn to systematic reviews and meta-analyses-and particularly abstracts of such articles-for clinical guidance. Thus, it is crucial that findings are not misrepresented in abstracts. In this study, we evaluated the use of spin (ie, the misreporting of study findings by overstating or selectively reporting efficacy results, minimizing harms, or making unwarranted clinical recommendations) in the abstracts of systematic reviews on erectile dysfunction.Entities:
Keywords: Abstracts; Erectile Dysfunction; Sexual Disorders; Spin
Year: 2020 PMID: 33291041 PMCID: PMC7930867 DOI: 10.1016/j.esxm.2020.10.012
Source DB: PubMed Journal: Sex Med ISSN: 2050-1161 Impact factor: 2.491
Figure 1Search strategies.
Spin types and frequencies (%) in abstracts (N = 102)
| 9 most severe types of spin | No. (%) of abstracts containing spin |
|---|---|
| 1) Conclusion contains recommendations for clinical practice not supported by the findings. | 5 (4.9) |
| 2) Title claims or suggests a beneficial effect of the experimental intervention not supported by the findings. | 1 (1) |
| 3) Selective reporting of or overemphasis on efficacy outcomes or analysis favoring the beneficial effect of the experimental intervention. | 11 (10.8) |
| 4) Conclusion claims safety based on non-statistically significant results with a wide confidence interval. | 0 (0) |
| 5) Conclusion claims the beneficial effect of the experimental treatment despite high risk of bias in primary studies. | 11 (10.8) |
| 6) Selective reporting of or overemphasis on harm outcomes or analysis favoring the safety of the experimental intervention. | 10 (9.8) |
| 7) Conclusion extrapolates the review's findings to a different intervention (ie, claiming efficacy of one specific intervention although the review covers a class of several interventions). | 5 (4.9) |
| 8) Conclusion extrapolates the review's findings from a surrogate marker or a specific outcome to the global improvement of the disease. | 1 (1) |
| 9) Conclusion claims the beneficial effect of the experimental treatment despite reporting bias. | 8 (7.8) |
Spin types as defined by Yavchitz et al.
AMSTAR 2 items and frequency of responses (N = 102)
| AMSTAR 2 item | Response, no. (%) | ||
|---|---|---|---|
| Yes | No | Partial yes | |
| 1) Did the research questions and inclusion criteria for the review include the elements of PICO? | 101 (99%) | 1 (1%) | 0 (0) |
| 2) Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? | 11 (10.8%) | 79 (77.5%) | 12 (11.7%) |
| 3) Did the review authors explain their selection of the study designs for inclusion in the review? | 88 (86.3%) | 14 (13.7%) | 0 (0) |
| 4) Did the review authors use a comprehensive literature search strategy? | 11 (10.8%) | 12 (11.8%) | 79 (77.4%) |
| 5) Did the review authors perform study selection in duplicate? | 65 (63.7%) | 37 (36.3%) | 0 (0) |
| 6) Did the review authors perform data extraction in duplicate? | 69 (67.6%) | 33 (32.4%) | 0 (0) |
| 7) Did the review authors provide a list of excluded studies and justify the exclusions? | 33 (32.4%) | 24 (23.5%) | 45 (44.1%) |
| 8) Did the review authors describe the included studies in adequate detail? | 44 (43.1%) | 8 (7.8%) | 50 (49.0%) |
| 9) Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? | 50 (49.0%) | 39 (38.2%) | 13 (12.7%) |
| 10) Did the review authors report on the sources of funding for the studies included in the review? | 7 (6.9%) | 95 (93.1%) | 0 (0) |
| 11) If meta-analysis was performed, did the review authors use appropriate methods for statistical combination of results? | 68 (88.3%) | 9 (11.7%) | 0 (0) |
| 12) If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? | 61 (79.2%) | 16 (20.8%) | 0 (0) |
| 13) Did the review authors account for RoB in primary studies when interpreting/discussing the results of the review? | 66 (64.7%) | 36 (35.3%) | 0 (0) |
| 14) Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? | 68 (66.7%) | 34 (33.3%) | 0 (0) |
| 15) If they performed quantitative synthesis did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? | 40 (51.9%) | 37 (48.1%) | 0 (0) |
| 16) Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review? | 79 (77.5%) | 23 (22.5%) | 0 (0) |
AMSTAR 2 = revised A MeaSurement Tool to Assess systematic Reviews; PICO = patient/population, intervention, comparison, outcomes.
25 articles did not perform a meta-analysis.
Figure 2Flow diagram of inclusion and exclusion criteria.
General characteristics of systematic reviews and meta-analyses
| Study characteristics | No. (%) of articles (N = 102) | |||
|---|---|---|---|---|
| Total | Abstract without spin | Abstract with spin | Odds ratio (95% CI) | |
| Intervention type | ||||
| Mixed | 8 | 6 | 2 | 1 [Ref] |
| Nonpharmacologic | 18 | 14 | 4 | 0.86 (0.12–6.01) |
| Pharmacologic | 68 | 42 | 26 | 1.86 (0.35–9.9) |
| Surgery | 8 | 8 | 0 | 1 |
| Article mentions adherence to PRISMA | ||||
| No | 67 | 48 | 19 | 1 [Ref] |
| Yes | 35 | 22 | 13 | 1.49 (0.63–3.55) |
| Publishing journal recommends adherence to PRISMA | ||||
| No | 41 | 29 | 12 | 1 [Ref] |
| Yes | 61 | 41 | 20 | 1.18 (0.50–2.78) |
| Funding source | ||||
| Not funded | 24 | 16 | 8 | 1 [Ref] |
| Industry | 11 | 10 | 1 | 0.20 (0.02–1.85) |
| Not mentioned | 46 | 31 | 15 | 0.97 (0.34–2.76) |
| Private | 6 | 3 | 3 | 2.00 (0.33–12.34) |
| Public | 15 | 10 | 5 | 1.00 (0.25–3.93) |
| AMSTAR 2 rating | ||||
| Critically low | 41 | 32 | 9 | 1 [Ref] |
| Low | 8 | 5 | 3 | 2.13 (0.43–10.68) |
| Moderate | 51 | 31 | 20 | 2.29 (0.91–5.81) |
| High | 2 | 2 | 0 | 1 |
| Journal 5-year impact factor | 4.04 (4.48) | 3.93 (4.11) | 4.26 (5.16) | 1.02 (0.92–1.12) |
| Year review was conducted (1997–2020) | 1.02 (0.95–1.11) | |||
AMSTAR 2 = revised A MeaSurement Tool to Assess systematic Reviews; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses.